CN104737021A - 用于治疗肝细胞癌的生物标志物 - Google Patents
用于治疗肝细胞癌的生物标志物 Download PDFInfo
- Publication number
- CN104737021A CN104737021A CN201380014334.8A CN201380014334A CN104737021A CN 104737021 A CN104737021 A CN 104737021A CN 201380014334 A CN201380014334 A CN 201380014334A CN 104737021 A CN104737021 A CN 104737021A
- Authority
- CN
- China
- Prior art keywords
- biomarker
- tcf
- level
- sample
- certain embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCC(C(C)=C=CC)C(*(C)C(CCC(*1)=O)C1=O)=O Chemical compound CCC(C(C)=C=CC)C(*(C)C(CCC(*1)=O)C1=O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586672P | 2012-01-13 | 2012-01-13 | |
| US61/586,672 | 2012-01-13 | ||
| PCT/US2013/021197 WO2013106686A1 (en) | 2012-01-13 | 2013-01-11 | Biomarkers for the treatment of hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104737021A true CN104737021A (zh) | 2015-06-24 |
Family
ID=47604231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380014334.8A Pending CN104737021A (zh) | 2012-01-13 | 2013-01-11 | 用于治疗肝细胞癌的生物标志物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8901110B2 (https=) |
| EP (1) | EP2802877A1 (https=) |
| JP (1) | JP2015504677A (https=) |
| CN (1) | CN104737021A (https=) |
| AU (1) | AU2013202104B2 (https=) |
| CA (1) | CA2871535A1 (https=) |
| MX (1) | MX2014008388A (https=) |
| WO (1) | WO2013106686A1 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108048568A (zh) * | 2017-12-25 | 2018-05-18 | 贵州省人民医院 | Plcd4基因作为胃腺癌转移诊断标志物的用途 |
| CN109266747A (zh) * | 2018-09-21 | 2019-01-25 | 中国医学科学院北京协和医院 | 与i型神经纤维瘤合并脊柱畸形病相关gpr56及其应用 |
| CN116064810A (zh) * | 2022-11-10 | 2023-05-05 | 杭州医学院 | CD24作为Hippo通路失活亚型肝细胞癌生物标志物的应用 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2428513T3 (en) | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
| JP5959543B2 (ja) | 2011-03-11 | 2016-08-02 | セルジーン コーポレイション | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンの固体形態、並びにそれらの医薬組成物及び使用 |
| ES2814952T3 (es) | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
| IL278381B2 (en) * | 2013-12-06 | 2024-08-01 | Celgene Corp | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer |
| CN103645259B (zh) * | 2013-12-12 | 2015-03-11 | 深圳海王药业有限公司 | 一种同时测定泊马度胺及其有关物质的方法 |
| WO2016060702A1 (en) * | 2014-10-13 | 2016-04-21 | Celgene Corporaton | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| EP3863615A4 (en) * | 2018-10-14 | 2022-08-03 | Lantern Pharma Inc. | METHODS OF TREATMENT OF CANCERS WITH SOLID TUMORS USING ILLUDINS AND BIOMARKERS |
| US20220289821A1 (en) * | 2018-11-29 | 2022-09-15 | Trillium Therapeutics Inc | Biomarkers for cd47 blockade therapy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7803783B2 (en) * | 2002-12-06 | 2010-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Use of WNT inhibitors to augment therapeutic index of chemotherapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1166651C (zh) * | 2001-06-08 | 2004-09-15 | 北京大学药学院 | 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物 |
| WO2011109237A2 (en) * | 2010-03-02 | 2011-09-09 | Emory University | Uses of noscapine and derivatives in subjects diagnosed with fap |
-
2013
- 2013-01-11 EP EP13701319.9A patent/EP2802877A1/en not_active Withdrawn
- 2013-01-11 CA CA2871535A patent/CA2871535A1/en not_active Withdrawn
- 2013-01-11 JP JP2014552323A patent/JP2015504677A/ja active Pending
- 2013-01-11 AU AU2013202104A patent/AU2013202104B2/en not_active Ceased
- 2013-01-11 MX MX2014008388A patent/MX2014008388A/es unknown
- 2013-01-11 CN CN201380014334.8A patent/CN104737021A/zh active Pending
- 2013-01-11 US US13/740,012 patent/US8901110B2/en active Active
- 2013-01-11 WO PCT/US2013/021197 patent/WO2013106686A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7803783B2 (en) * | 2002-12-06 | 2010-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Use of WNT inhibitors to augment therapeutic index of chemotherapy |
Non-Patent Citations (2)
| Title |
|---|
| DONG HONG ZHAO ET AL: "Aberrant expression and function of TCF4 in the proliferation of hepatocellular carcinoma cell line BEL-7402", 《CELL RESEARCH》 * |
| WEI WEI ET AL: "Small molecule antagonists of Tcf4/I2-catenin complex inhibit the growth of HCC cells in vitro", 《INTERNATIONAL JOURNAL OF CANCER》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108048568A (zh) * | 2017-12-25 | 2018-05-18 | 贵州省人民医院 | Plcd4基因作为胃腺癌转移诊断标志物的用途 |
| CN108048568B (zh) * | 2017-12-25 | 2021-02-02 | 贵州省人民医院 | Plcd4基因作为胃腺癌转移诊断标志物的用途 |
| CN109266747A (zh) * | 2018-09-21 | 2019-01-25 | 中国医学科学院北京协和医院 | 与i型神经纤维瘤合并脊柱畸形病相关gpr56及其应用 |
| CN109266747B (zh) * | 2018-09-21 | 2021-07-27 | 中国医学科学院北京协和医院 | 与i型神经纤维瘤合并脊柱畸形病相关gpr56及其应用 |
| CN116064810A (zh) * | 2022-11-10 | 2023-05-05 | 杭州医学院 | CD24作为Hippo通路失活亚型肝细胞癌生物标志物的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013202104A1 (en) | 2013-08-01 |
| MX2014008388A (es) | 2014-11-14 |
| US20130183675A1 (en) | 2013-07-18 |
| JP2015504677A (ja) | 2015-02-16 |
| EP2802877A1 (en) | 2014-11-19 |
| WO2013106686A1 (en) | 2013-07-18 |
| US8901110B2 (en) | 2014-12-02 |
| CA2871535A1 (en) | 2013-07-18 |
| AU2013202104B2 (en) | 2015-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8901110B2 (en) | Use of biomarkers in methods for the treatment of hepatocellular carcinoma | |
| JP7142612B2 (ja) | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 | |
| US20210389328A1 (en) | Methode for identifying subgroups of circulating tumor cells (ctcs) in the ctc population of a biological sample | |
| US20170242014A1 (en) | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies | |
| US20180231561A1 (en) | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies | |
| Lin et al. | Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer | |
| Werner et al. | Expression of epithelial mesenchymal transition and cancer stem cell markers in circulating tumor cells | |
| CN108883115A (zh) | 用parp抑制剂治疗小细胞肺癌 | |
| JP2020523022A (ja) | 免疫療法に反応する肝細胞癌のクラスの検出および治療方法 | |
| Shan et al. | Gradually increased G olgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients | |
| Xie et al. | Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma | |
| JP2025111438A (ja) | イルジンおよびバイオマーカーを使用した固形腫瘍癌の治療方法 | |
| KR20120121941A (ko) | 중추신경계 림프종 진단용 조성물 및 이를 이용한 중추신경계 림프종 진단 키트 | |
| AU2017299513A1 (en) | Biomarkers for detection and treatment of mast cell activity-associated disorders | |
| EP3676295B1 (en) | Phenotypic profiling of hepatocellular carcinoma circulating tumor cells for treatment selection | |
| JP2022153482A (ja) | 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ | |
| Tsaur et al. | Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer | |
| JP2011505807A (ja) | キナゾリノン化合物による治療をモニタリングするためのバイオマーカー | |
| Romano | Hepatocarcinoma in chronic viral hepatitis: from epidemiological data, through new pathophysiological findings, up to new possible clinical tools | |
| Deng et al. | What Is the Future of Circulating Tumor Cells in Colorectal Cancer? | |
| Corrò | Dissecting tumor heterogeneity and cancer stem cell properties in clear cell renal cell carcinoma | |
| Corrò | Erlangung der naturwissenschaftlichen Doktorwürde (Dr. sc. nat.) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultät der | |
| HK40031046A (en) | Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy | |
| HK1260828A1 (en) | Treatment of small cell lung cancer with a parp inhibitor | |
| PL227588B1 (pl) | Sposób wykrywania in vitro agresywnych komórek nowotworowych o fenotypie macierzystym i/lub mezenchymalnym, zestaw do wykrywania oraz zastosowanie sposobu do wykrywania in vitro agresywnych komórek nowotworowych o fenotypie macierzystym i/lub mezenchymalnym do przewidywania przebiegu raka piersi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150624 |
|
| WD01 | Invention patent application deemed withdrawn after publication |